CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells.
Humans
Hepatitis B virus
/ immunology
Animals
Mice
Hepatitis B Surface Antigens
/ immunology
Receptors, Chimeric Antigen
/ immunology
Antibodies, Monoclonal
/ immunology
Immunotherapy, Adoptive
Hepatitis B
/ immunology
Broadly Neutralizing Antibodies
/ immunology
B-Lymphocytes
/ immunology
T-Lymphocytes
/ immunology
HBsAg
broad neutralization
chimeric antigen receptor
hepatitis B virus envelope proteins
human monoclonal antibody
linear epitope
single B cell sorting
tonic signaling
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
18
11
2023
accepted:
18
03
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
epublish
Résumé
To design new CARs targeting hepatitis B virus (HBV), we isolated human monoclonal antibodies recognizing the HBV envelope proteins from single B cells of a patient with a resolved infection. HBV-specific memory B cells were isolated by incubating peripheral blood mononuclear cells with biotinylated hepatitis B surface antigen (HBsAg), followed by single-cell flow cytometry-based sorting of live, CD19
Identifiants
pubmed: 38711498
doi: 10.3389/fimmu.2024.1340619
pmc: PMC11072186
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Receptors, Chimeric Antigen
0
Antibodies, Monoclonal
0
Broadly Neutralizing Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1340619Informations de copyright
Copyright © 2024 Schreiber, Dressler, Loffredo-Verde, Asen, Färber, Wang, Groll, Chakraborty, Kolbe, Kreer, Kosinska, Simon, Urban, Klein, Riddell and Protzer.
Déclaration de conflit d'intérêts
UP is a co-founder, shareholder, and SCG Cell Therapy Pte Ltd board member. UP received personal fees from Abbott, Abbvie, Arbutus, Gilead, GSK, J&J, MSD, Roche, Sanofi, Sobi, and Vaccitech. SR was a founder, has served as an advisor, and has patents licensed to Juno Therapeutics; is a founder of and holds equity in Lyell Immunopharma; and has served on the advisory boards for Adaptive Biotechnologies and Nohla. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.